Skip to main content

Table 8 The impact of expression status of metabolism-related proteins on prognosis by univariate analysis

From: Metabolic phenotypes in primary unknown metastatic carcinoma

Clinicopathologic parameters

No. of patients (n = 59*) (%)

Overall survival

No. of cases

Patient death

 

Median survival (95% CI) (months)

P -value

Glut-1 (T)

    

0.101

 Negative

34

13

 

74 (49–98)

 

 Positive

25

5

 

55 (42–68)

 

Glut-1 (S)

  

N/A

 

N/A

 Negative

59

18

 

84 (66–102)

 

 Positive

0

0

 

N/A

 

CAIX (T)

    

0.272

 Negative

51

17

 

82 (63–101)

 

 Positive

8

1

 

54 (30–79)

 

CAIX (S)

    

N/A

 Negative

57

18

 

N/A

 

 Positive

2

0

 

N/A

 

MCT4 (T)

    

0.759

 Negative

19

5

 

87 (59–115)

 

 Positive

40

13

 

80 (57–103)

 

MCT4 (S)

    

0.631

 Negative

34

9

 

94 (73–115)

 

 Positive

25

9

 

43 (29–57)

 

GLS1 (T)

    

0.139

 Negative

39

10

 

49 (38–60)

 

 Positive

20

8

 

73 (42–103)

 

GLS1 (S)

    

0.721

 Negative

50

15

 

84 (65–104)

 

 Positive

9

3

 

46 (22–69)

 

GDH (T)

    

1.000

 Negative

7

2

 

28 (14–39)

 

 Positive

52

16

 

85 (66–104)

 

GDH (S)

    

0.786

 Negative

44

13

 

90 (72–109)

 

 Positive

15

5

 

40 (19–60)

 

ASCT2 (T)

    

0.506

 Negative

38

13

 

78 (54–101)

 

 Positive

21

5

 

36 (27–45)

 

ASCT2 (S)

    

0.227

 Negative

56

16

 

87 (68–105)

 

 Positive

3

2

 

16 (1–32)

 

ATP synthase (T)

    

0.653

 Negative

2

1

 

10 (10–10)

 

 Positive

57

17

 

85 (67–104)

 

ATP synthase (S)

    

0.535

 Negative

48

14

 

88 (68–107)

 

 Positive

11

4

 

23 (12–34)

 

SDHA (T)

    

0.906

 Negative

3

1

 

28 (13–43)

 

 Positive

56

17

 

84 (66–103)

 

SDHA (S)

    

0.588

 Negative

44

13

 

90 (70–109)

 

 Positive

15

5

 

37 (15–58)

 

SDHB (T)

    

0.166

 Negative

23

5

 

86 (56–115)

 

 Positive

36

13

 

79 (57–102)

 

SDHB (S)

    

0.923

 Negative

51

16

 

84 (65–103)

 

 Positive

8

2

 

27 (16–37)

 
  1. *Out of 77 patients, clinical follow-up data were available in 59 patients.